Literature DB >> 3700283

In-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.

K V Rolston, B LeBlanc, D H Ho.   

Abstract

The activity of a novel macrolide, RU 28965, was compared to that of erythromycin against Gram-positive organisms isolated mainly from cancer patients. RU 28965 was active against streptococci including Streptococcus pneumoniae and streptococcal groups A, B and G. It was also active against methicillin-susceptible staphylococci, Bacillus cereus and Listeria monocytogenes. Its activity against these organisms was generally equal to that of erythromycin. RU 28965 was moderately active against enterococci and inactive against JK diphtheroids and three different species of coagulase-negative staphylococci. Organisms resistant to erythromycin were also resistant to RU 28965.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3700283     DOI： 10.1093/jac/17.2.161

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  9 in total

Review 1.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II).

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

2.  Concentrations of roxithromycin (RU 28965) in serum and in sinus mucosa.

Authors:  A Kropec; E Schmidt-Eisenlohr; F D Daschner
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

3.  Roxithromycin bioassay procedures for human plasma, urine and milk specimens [corrected and issued with original paging in Eur J Clin Microbiol 1986 Dec;5(6)].

Authors:  A L Barry; R R Packer
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

4.  Toxicity, uptake, and subcellular distribution in rat hepatocytes of roxithromycin, a new semisynthetic macrolide, and erythromycin base.

Authors:  P Villa; D Sassella; M Corada; I Bartosek
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

5.  Activity of new antimicrobial agents against Listeria monocytogenes.

Authors:  K V Rolston; G P Bodey
Journal:  Eur J Clin Microbiol       Date:  1987-12       Impact factor: 3.267

6.  Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.

Authors:  K V Rolston; D H Ho; B LeBlanc; G P Bodey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-01       Impact factor: 3.267

7.  Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia.

Authors:  B J Zeluff; P Lowe; H J Koornhof; L O Gentry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

8.  Prevention of bacteremia caused by alpha-hemolytic streptococci by roxithromycin (RU-28 965) in granulocytopenic patients receiving ciprofloxacin.

Authors:  M Rozenberg-Arska; A Dekker; L Verdonck; J Verhoef
Journal:  Infection       Date:  1989 Jul-Aug       Impact factor: 3.553

Review 9.  Roxithromycin. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  R A Young; J P Gonzalez; E M Sorkin
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.